RANKL inhibitors for osteosarcoma treatment: hope and caution.
作者信息
Trinidad Eva M, González-Suárez Eva
机构信息
Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, IDIBELL, Barcelona, Spain.
出版信息
Ann Transl Med. 2016 Dec;4(24):534. doi: 10.21037/atm.2016.12.10.
Abstract
摘要
相似文献
1
RANKL inhibitors for osteosarcoma treatment: hope and caution.
Ann Transl Med. 2016 Dec;4(24):534. doi: 10.21037/atm.2016.12.10.
2
Formulated siRNAs targeting Rankl prevent osteolysis and enhance chemotherapeutic response in osteosarcoma models.
J Bone Miner Res. 2011 Oct;26(10):2452-62. doi: 10.1002/jbmr.455.
3
4
Osteoprotegerin activates osteosarcoma cells that co-express RANK and RANKL.
Exp Cell Res. 2015 Oct 15;338(1):32-8. doi: 10.1016/j.yexcr.2015.08.001. Epub 2015 Aug 5.
5
RANKL directly induces bone morphogenetic protein-2 expression in RANK-expressing POS-1 osteosarcoma cells.
Int J Oncol. 2006 Jan;28(1):261-9.
6
Bisphosphonates inhibit osteosarcoma-mediated osteolysis via attenuation of tumor expression of MCP-1 and RANKL.
J Bone Miner Res. 2014 Jun;29(6):1431-45. doi: 10.1002/jbmr.2182.
7
The Intrinsic and Extrinsic Implications of RANKL/RANK Signaling in Osteosarcoma: From Tumor Initiation to Lung Metastases.
Cancers (Basel). 2018 Oct 24;10(11):398. doi: 10.3390/cancers10110398.
8
RANK and RANK ligand expression in primary human osteosarcoma.
J Bone Oncol. 2015 Jul 29;4(3):59-68. doi: 10.1016/j.jbo.2015.06.002. eCollection 2015 Sep.
9
The presence of RANKL-OPG complex in human osteosarcoma U2OS.
J Immunoassay Immunochem. 2013;34(4):356-64. doi: 10.1080/15321819.2012.741640.
10
Impact of RANK signalling on survival and chemotherapy response in osteosarcoma.
Pathology. 2014 Aug;46(5):411-5. doi: 10.1097/PAT.0000000000000116.
引用本文的文献
1
The Osteoclast Traces the Route to Bone Tumors and Metastases.
Front Cell Dev Biol. 2022 May 13;10:886305. doi: 10.3389/fcell.2022.886305. eCollection 2022.
2
Osteosarcoma mechanobiology and therapeutic targets.
Br J Pharmacol. 2022 Jan;179(2):201-217. doi: 10.1111/bph.15713. Epub 2021 Dec 21.
3
Evaluation of the Receptor Activator of Nuclear Factor Kappa B Ligand (RANKL) Expression in Osteosarcoma and Its Association with the Clinicopathological Data.
Asian Pac J Cancer Prev. 2021 Mar 1;22(3):741-747. doi: 10.31557/APJCP.2021.22.3.741.
4
Understanding and Modeling Metastasis Biology to Improve Therapeutic Strategies for Combating Osteosarcoma Progression.
Front Oncol. 2020 Jan 31;10:13. doi: 10.3389/fonc.2020.00013. eCollection 2020.
5
Emerging Anticancer Potentials of Selenium on Osteosarcoma.
Int J Mol Sci. 2019 Oct 25;20(21):5318. doi: 10.3390/ijms20215318.
6
Emerging trends in immunotherapy for pediatric sarcomas.
J Hematol Oncol. 2019 Jul 16;12(1):78. doi: 10.1186/s13045-019-0756-z.
本文引用的文献
1
T-Cell-Based Immunotherapy for Osteosarcoma: Challenges and Opportunities.
Front Immunol. 2016 Sep 14;7:353. doi: 10.3389/fimmu.2016.00353. eCollection 2016.
2
RANK and RANK ligand expression in primary human osteosarcoma.
J Bone Oncol. 2015 Jul 29;4(3):59-68. doi: 10.1016/j.jbo.2015.06.002. eCollection 2015 Sep.
3
RANK Signaling Blockade Reduces Breast Cancer Recurrence by Inducing Tumor Cell Differentiation.
Cancer Res. 2016 Oct 1;76(19):5857-5869. doi: 10.1158/0008-5472.CAN-15-2745. Epub 2016 Aug 1.
4
Osteosarcoma: Current Treatment and a Collaborative Pathway to Success.
J Clin Oncol. 2015 Sep 20;33(27):3029-35. doi: 10.1200/JCO.2014.59.4895. Epub 2015 Aug 24.
5
Effect of denosumab on recurrent giant cell reparative granuloma of the lumbar spine.
Spine (Phila Pa 1976). 2015 May 15;40(10):E601-8. doi: 10.1097/BRS.0000000000000862.
6
RANK expression as a prognostic and predictive marker in breast cancer.
Breast Cancer Res Treat. 2014 Jun;145(2):307-15. doi: 10.1007/s10549-014-2955-1. Epub 2014 Apr 16.
7
Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab.
Nat Rev Drug Discov. 2012 May;11(5):401-19. doi: 10.1038/nrd3705.
8
RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis.
Cancer Res. 2012 Jun 1;72(11):2879-88. doi: 10.1158/0008-5472.CAN-12-0044. Epub 2012 Apr 10.
9
RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis.
Nature. 2010 Nov 4;468(7320):103-7. doi: 10.1038/nature09495. Epub 2010 Sep 29.
10
Prkar1a is an osteosarcoma tumor suppressor that defines a molecular subclass in mice.
J Clin Invest. 2010 Sep;120(9):3310-25. doi: 10.1172/JCI42391. Epub 2010 Aug 9.
Zotero 插件